Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

Novavax said on Wednesday the U.S. Food and Drug Administration had asked the company to produce more data on its COVID-19 ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

BofA notes that Novavax (NVAX) shares are up 21% after announcing the company has received communication from the FDA for a post marketing ...

Novavax (NVAX) issued the following update on the FDA BLA for the company’s COVID-19 vaccine: “We believe that our Biologics License ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay. The Secretary of Health and Human Services ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a ...

Novavax's $500M Sanofi partnership with a potential $700M in milestones provides stability as the company transitions to a partnership-focused strategy. Health Secretary Kennedy's claim that ...

Novavax recipients had 1.7 symptoms on average vs. 2.8 for Pfizer-BioNTech in SHIELD-Utah. 24.2% of Novavax recipients had Grade 2+ symptoms vs. 43.8% of Pfizer-BioNTech recipients. Markets are ...